This transcript has been edited for clarity.
Lidia Schapira, MD: Hello. I'm Dr Lidia Schapira, and welcome to Medscape InDiscussion Breast Cancer. Today we're talking about how BRCA status impacts choices of therapy for patients with early-stage breast cancer. Since genetic testing has become widely available and we now understand that BRCAness impacts response to treatment, I'm delighted that my guest today will help us understand how we can apply this new knowledge to our clinical practice. My guest today is Dr Nadine Tung, professor of medicine at Harvard Medical School and director of the Cancer Risk and Prevention Program at Beth Israel Deaconess Medical Center. Welcome, Nadine.
Nadine Tung, MD: Hi, Lidia. Thank you so much for this invitation.
Schapira: Such a great opportunity for us to chat about a topic that I know you've been studying for your entire career. In fact, you were one of the earliest translational researchers to really think about treatment choices for patients who have BRCA-positive tumors. Tell us a little bit about how you think that having a BRCA mutation affects the way we should approach the treatment of breast cancer.
Tung:Well, it is very exciting because for so many years we did the genetic testing for
